Telmisartan is a specific angiotensin II receptor (AT1 type) antagonist, which binds to the angiotensin II receptor AT1 subtype with high affinity and has no partial agonist effect. Telmisartan can reduce blood aldosterone levels, does not inhibit human plasma renin or ion channels, does not inhibit angiotensin converting enzyme, and does not cause adverse reactions such as enhanced bradykinin action. Its antihypertensive effect is comparable to other types of representative antihypertensive drugs.

Not clearly described

It exerts antiplatelet and vasodilator effects by inhibiting the activity of phosphodiesterase in platelets and vascular smooth muscle, increasing the cAMP concentration in platelets and smooth muscle; inhibiting the initial and secondary platelet aggregation and release reactions induced by ADP, adrenaline, collagen and arachidonic acid; not interfering with the synthesis of vascular protective prostacyclin by vascular endothelial cells; and increasing tissue blood flow in the foot and gastrocnemius muscles in patients with chronic arterial occlusion, thereby increasing the lower limb blood pressure index, skin blood flow and skin temperature of the limbs, and improving intermittent claudication.